Shire PLC is a specialty biopharmaceutical company. They have a global sales and marketing infrastructure with a broad portfolio of products and direct marketing capability in the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain.

At Shire, we enable people with life altering conditions to lead better lives. We focus on developing and delivering innovative treatments for patients with rare diseases and other specialty conditions. 

To realize our aspiration to become a leading global biotech, our efforts are concentrated on four key strategic drivers: growth, innovation, efficiency, and people. Our priorities are to drive optimal performance of our existing products, increase patient access to these medicines, and to build our pipeline through research and development and partnerships in order to deliver new medicines to patients.
Company Growth (employees)
Type
Public
HQ
Jersey, JE
Founded
1986
Size (employees)
23,906 (est)
Website
shire.com
Shire was founded in 1986 and is headquartered in Jersey, JE

Key People/Management at Shire

Flemming Ornskov

Flemming Ornskov

Chief Executive Officer
Bill Mordan

Bill Mordan

General Counsel and Company Secretary
Joanne Cordeiro

Joanne Cordeiro

Chief Human Resources Officer
Perry Sternberg

Perry Sternberg

Head of US Commercial
Kim Stratton

Kim Stratton

Head of International Commercial
BSCHE Matt Walker

BSCHE Matt Walker

Head of Technical Operations

Shire Office Locations

Shire has offices in Jersey, Dublin, Lexington, Zug and in 37 other locations
Jersey, JE (HQ)
No. 99854, 22 Grenville Street, St Helier
São Paulo, BR
Av. das Nações Unidas, 14.171, 5o andar
Saint-Laurent, CA
2250 Alfred-Nobel Blvd, Suite 500
Dublin, IE
5 Riverwalk
Zug, CH
Zählerweg 10
Lexington, US
300 Shire Way
Show all (41)

Shire Financials and Metrics

Shire Financials

Shire's revenue was reported to be £47.6 m in FY, 2016
USD

Revenue (Q1, 2017)

3.6 b

Gross profit (Q1, 2017)

2.2 b

Gross profit margin (Q1, 2017), %

63%

Net income (Q1, 2017)

375 m

Market capitalization (27-Oct-2017)

42.4 b

Closing share price (27-Oct-2017)

138.2

Cash (31-Mar-2017)

369 m
Shire's current market capitalization is $42.4 b.
GBPFY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Revenue

108 m98.3 m114 m111.4 m103.4 m109.3 m120.6 m122.3 m67.1 m58.2 m47.6 m

Revenue growth, %

4824%7%78%

Operating expense total

159.8 m95.1 m100.7 m104.7 m106.5 m113.1 m120.3 m123.2 m70.1 m55.9 m46.4 m

EBITDA

32.9 m40.9 m34.4 m(1.1 m)(1.5 m)3 m1.7 m(433 k)3.7 m1.8 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

1.6 b1.7 b1.7 b2.4 b3.5 b3.6 b

Cost of goods sold

228 m262.7 m248.6 m778.1 m1.7 b1.3 b

Gross profit

1.3 b1.4 b1.5 b1.7 b1.7 b2.2 b

Gross profit Margin, %

85%84%85%68%50%63%
GBPFY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Cash

4 k528.8 m

Accounts Receivable

2.6 b

Inventories

455.3 m544.8 m635.4 m3.6 b

Current Assets

51.1 m75.3 m116.7 m143.6 m148.2 m145.6 m148.6 m156.6 m151.6 m158.9 m7.5 b
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

153.6 m467.7 m74.3 m64 m44.9 m69 m693.4 m728.6 m369 m

Accounts Receivable

1.1 b1.1 b1.1 b1.1 b1.3 b1.3 b2.4 b2.6 b2.6 b

Inventories

585 m548.9 m588.7 m632.8 m608.9 m680 m5.8 b4.9 b3.3 b

Current Assets

2.6 b2.9 b2.5 b2.5 b2.7 b2.4 b9.7 b8.9 b7.1 b
    GBPFY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

    Net Income

    (65.5 m)7.5 m15.1 m4.7 m(1.9 m)(2.7 m)1.6 m1.6 m(2.9 m)2.9 m2.5 m

    Depreciation and Amortization

    324.4 m407.3 m637.2 m1.5 b

    Accounts Receivable

    (210 m)(701.7 m)

    Cash From Operating Activities

    2.7 b
    USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

    Net Income

    753.5 m1.2 b410.4 m570 m1 b419 m375 m

    Depreciation and Amortization

    204.8 m307.1 m120.6 m291.8 m457.4 m168.9 m429.8 m877.8 m486.9 m

    Accounts Receivable

    (37.3 m)(92.1 m)(85.1 m)(84.9 m)(288.1 m)(100.9 m)(181 m)(411.2 m)(35.3 m)

    Cash From Operating Activities

    1.1 b1.7 b561.6 m1 b1.6 b389.5 m980.4 m1.5 b459.1 m
      USDY, 2017

      Revenue/Employee

      149.4 k

      Financial Leverage

      2.2 x
      Show all financial metrics

      Shire Operating Metrics

      FY, 2014FY, 2015FY, 2016

      Countries

      6872100

      Projects in R&D Pipeline

      272937

      Phase II Trials

      11610

      Phase III Trials

      71417
      Show all operating metrics

      Shire Market Value History

      Shire Revenue Breakdown

      Shire's employees are reported to be approximately 52% female and 48% male.

      Shire Median Salaries

      Source: 25 public H-1B filings from Shire
      Show all human capital metrics

      Shire's Web-traffic and Trends

      Shire Online and Social Media Presence

      Shire News and Updates

      For Shire, more margin pressure plus fewer growth sparks make for underwhelming 2018

      One analyst takeaway from Shire’s 2018 outlook: Consensus earnings estimates probably need to come down. On Wednesday, the company said it was predicting $14.90 to $15.50 per share, a range that sits below the $15.94 Wall Street had been expecting. And that “initial 2018 outlook suggests EPS needs t…

      Judge that nixed Juxtapid's DOJ settlement prompts Aegerion to admit its off-label sins

      Aegerion agreed to pay $36 million to the feds in a Juxtapid marketing case, but a federal judge thought that wasn't good enough. Tuesday, he sentenced the company to pay the same total—only this time, patients got a chunk of the settlement.

      Roche follows Shire to Europe with hemophilia approval for Hemlibra

      Roche and Shire are taking their hemophilia battle across the pond. Following Shire’s EU approval for Adynovi last week, Roche has nabbed a European green light for Hemlibra, a first-in-class hemophilia A medication that analysts expect to reach blockbuster heights.

      Worldwide Eye Allergy Treatment Market Is Expected To Touch USD 6845.3 Million By 2023

      Market research future has a half cooked research report on global eye allergy treatment market. The global eye allergy treatment market is growing continuously and expected to grow at a CAGR of 5.2% from 2017 to 2023 Posted via Industry Today. Follow us on Twitter @IndustryToday

      Blood Banking Global Market 2018: Key Players – American Red Cross, Japan Red Cross Society, New York Blood Center, America’s Blood Centers, Shire (Baxalta)

      Blood Banking -Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2023 Posted via Industry Today. Follow us on Twitter @IndustryToday

      Shire set for in-house production of rare disease drug Cinryze after shortage issues

      Shire decided to take some production of Cinryze in-house after problems at a contractor last year led to a shortage. The drugmaker said today that with an FDA approval, it will soon start manufacturing the rare disease drug at a site in Europe.
      Show more

      Shire Company Life and Culture

      You may also be interested in